Multiple Sclerosis Relapse Rates and Healthcare Costs with Generic Glatiramer Acetate: A Retrospective Claims Analysis of US Health Plan Data

被引：0
|
作者：
Kantor, Daniel [1 ]
Grabner, Michael [2 ]
Zhang, Xian [2 ]
Balu, Sanjeev [3 ]
Hall, Steven [3 ]
机构：
[1] Florida Atlantic Univ, Boca Raton, FL 33431 USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Sandoz Inc, Princeton, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P129
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [1] Multiple Sclerosis (MS) Relapse Rates and Healthcare Costs with Generic Glatiramer Acetate: a Retrospective Claims Analysis of US Health Plan Data
    Hall, Steven
    Balu, Sanjeev
    Grabner, Michael
    Zhang, Xiam
    Kantor, Daniel
    NEUROLOGY, 2019, 92 (15)
  • [2] A RETROSPECTIVE CLAIMS ANALYSIS OF US HEALTH PLAN COMMERCIAL INSURANCE DATA ASSESSING HEALTHCARE COSTS AND RELAPSE RATES IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH GENERIC GLATIRAMER ACETATE
    Greenberg, B.
    Grabner, M.
    Zhang, X.
    Balu, S.
    Hall, S.
    Kantor, D.
    VALUE IN HEALTH, 2019, 22 : S272 - S272
  • [3] Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate
    Greenberg, Benjamin
    Hall, Steven
    Grabner, Michael
    Balu, Sanjeev
    Zhang, Xian
    Kantor, Daniel
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (07) : 1167 - 1175
  • [4] Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis
    Bergvall, Niklas
    Makin, Charles
    Lahoz, Raquel
    Agashivala, Neetu
    Pradhan, Ashish
    Capkun, Gorana
    Petrilla, Allison
    Karkare, Swapna U.
    McGuiness, Catherine Balderston
    Korn, Jonathan R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1647 - 1656
  • [5] Multiple sclerosis relapse resolution with corticosteroid alternatives: a retrospective claims analysis of us health plan data
    Nazareth, T.
    Zhang, X.
    Yu, T. -C.
    Gu, T.
    Deshpande, G.
    Mahler, N.
    Waltrip, R.
    Tan, H.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 900 - 901
  • [6] Relapse rates among patients with multiple sclerosis who switch from interferon therapy to fingolimod or glatiramer acetate: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 276 - 276
  • [7] Relapse rates among patients with a history of relapses treated with fingolimod compared with interferons or glatiramer acetate for the treatment of multiple sclerosis: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 277 - 278
  • [8] Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
    Bergvall, Niklas
    Makin, Charles
    Lahoz, Raquel
    Agashivala, Neetu
    Pradhan, Ashish
    Capkun, Gorana
    Petrilla, Allison A.
    Karkare, Swapna U.
    McGuiness, Catherine Balderston
    Korn, Jonathan R.
    PLOS ONE, 2014, 9 (02):
  • [9] Multiple Sclerosis Relapse Rates, Before, During, and After Pregnancy: a US Retrospective Claims Database Analysis
    Phillips, Amy L.
    Houtchens, Maria K.
    Edwards, Natalie C.
    NEUROLOGY, 2017, 88
  • [10] MULTIPLE SCLEROSIS: REAL-WORLD HEALTHCARE COSTS IN A LARGE US HEALTH PLAN
    Sanchirico, M.
    Ma, I
    Caldwell, A.
    Mudumby, P.
    Hashemi, L.
    Dufour, R.
    VALUE IN HEALTH, 2016, 19 (07) : A629 - A629
12345